Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,254.14 | 58.98 | -0.71% |
| DAX 40 | 25,284.34 | 68.05 | -0.27% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,235.64 | 3.30 | -0.03% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |